Tag Archive for ‘CTIC’

Cell Therapeutics fell 14.49% to close Friday at $1.18, snapping a five-day rally. Over 4.69 million shares traded hands during the session, versus the 10-day average of 1.62 million.  The stock has a 52-week range of $0.95 – $3.33.  It is currently above its 50-day moving average of $1.16 and below its 200-day moving average of $1.37. Shares of CTIC - Continue Reading »

Cell Therapeutics Inc. (Nasdaq: CTIC) this morning reported its first-quarter results and accomplishments, reviewing the status of its cancer drug candidate pixantrone and maintaining the target to get the medicine’s regulatory approval by the end of 2011. The company had no revenue in Q1 2011 and reported that it lost $51.0 million, compared to 44.2 million in the Q1 2010. - Continue Reading »

Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of novel treatments for cancer.  It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer. The Company is focused on developing pixantrone, OPAXIO, brostallicin and bisplantinates. Pixantrone - Continue Reading »

Cell Therapeutics Inc. (Nasdaq: CTIC) slipped nearly 2% this morning shortly after the company reported that its appeal to the U.S. Food and Drug Administration (FDA) for pixantrone in aggressive non-Hodgkin’s lymphoma would be ruled in the second quarter of 2011. Following discussions with the FDA, Cell Therapeutics announced a new clinical trial of pixantrone, which could likely postpone the - Continue Reading »

*Financial status indicator is deficient: Issuer failed to meet NASDAQ continued listing requirements. Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of novel treatments for cancer.  It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat - Continue Reading »

*Financial status indicator is deficient: Issuer failed to meet NASDAQ continued listing requirements. Cell Therapeutics Inc. (CTIC) engages in the development, acquisition and commercialization of novel treatments for cancer.  It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat - Continue Reading »

Continuing my series of reader/subscriber suggested emails, I bring you Pluristem Technologies (PSTI). I’m not sure that the guy who emailed me this one doesn’t work for the company or the IR firm.  The email came right around the time that PSTI issued a flurry of press releases (Early July).  I deliberately waited over a month just to see “where - Continue Reading »